Global Newswire, 27 April 2020
BOSTON, April 27, 2020 (GLOBE NEWSWIRE) — Today, research analyst Citron Research published a report calling Inovio (INO) “The COVID-19 Version of Theranos,” in which Citron slashed its target price for Inovio common stock by 93%.
Dr Left has a $1 target stock is $11 ( you know he shorted at $16-17 and covered already never waiting for his $1 target SHORT AND DISTORT for a quick profit